ETWO – INVESTOR ACTION NOTICE: The Schall Law Firm Announces it is Investigating Claims Against E2open Parent Holdings, Inc. and Encourages Investors with Losses to Contact the Firm

LOS ANGELES, CA / ACCESSWIRE / May 28, 2023 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of E2open Parent Holdings, Inc. (“E2open” or “the Company”) (NYSE: ETWO) for violations of the securities laws.

https://www.accesswire.com/users/newswire/images/718659/1schall-logo.jpg

The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.

If you are a shareholder who suffered a loss, click here to participate.

We also encourage you to contact Brian Schall of the Schall Law Firm, 2049 Century Park East, Suite 2460, Los Angeles, CA 90067, at 310-301-3335, to discuss your rights free of charge. You can also reach us through the firm’s website at www.schallfirm.com, or by email at [email protected]

The class in this case has not yet been certified, and until certification occurs, you are not represented by an attorney. If you choose to take no action, you can remain an absent class member.

The Schall Law Firm represents investors around the world and specializes in securities class action lawsuits and shareholder rights litigation.

This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and rules of ethics.

CONTACT:

The Schall Law Firm
Brian Schall, Esq.
310-301-3335
[email protected]
www.schallfirm.com

SOURCE: The Schall Law Firm

RADI – SHAREHOLDER ACTION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Radius Global Infrastructure, Inc. and Encourages Investors with Losses to Contact the Firm

LOS ANGELES, CA / ACCESSWIRE / May 28, 2023 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors in Radius Global Infrastructure, Inc. (“Radius” or “the Company”) (NASDAQ: RADI) for potential breaches of fiduciary duty on the part of its directors and management in connection with the Company’s agreement to be acquired by EQT Active Core Infrastructure and Public Sector Pension Investment Board (“PSP”).

https://www.accesswire.com/users/newswire/images/718659/1schall-logo.jpg

The investigation focuses on determining if the Radius Board breached its fiduciary duties to shareholders by failing to conduct a fair process prior to its March 1, 2023, announcement, and whether EQT Active Core Infrastructure and PSP are underpaying for the Company.

If you are a shareholder, click here to participate.

We also encourage you to contact Brian Schall of the Schall Law Firm, 2049 Century Park East, Suite 2460, Los Angeles, CA 90067, at 310-301-3335, to discuss your rights free of charge. You can also reach us through the firm’s website at www.schallfirm.com, or by email at [email protected]

The Schall Law Firm represents investors around the world and specializes in securities class action lawsuits and shareholder rights litigation.

This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and rules of ethics.

CONTACT:

The Schall Law Firm
Brian Schall, Esq.
310-301-3335
[email protected]
www.schallfirm.com

SOURCE: The Schall Law Firm

FOCS – SHAREHOLDER ACTION NOTICE: The Schall Law Firm Announces it is Investigating Claims Focus Financial Partners Inc. and Encourages Investors with Losses to Contact the Firm

LOS ANGELES, CA / ACCESSWIRE / May 28, 2023 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors in Focus Financial Partners Inc. (“Focus Financial Partners” or “the Company”) (NASDAQ: FOCS) for potential breaches of fiduciary duty on the part of its directors and management in connection with the Company’s agreement to be acquired by Clayton Dubilier & Rice, LLC (“CD&R”).

https://www.accesswire.com/users/newswire/images/718659/1schall-logo.jpg

The investigation focuses on determining if Focus Financial Partners’ Board breached its fiduciary duties to shareholders by failing to conduct a fair process and whether CD&R is underpaying for the Company.

If you are a shareholder, click here to participate.

We also encourage you to contact Brian Schall of the Schall Law Firm, 1880 Century Park East, Suite 404, Los Angeles, CA 90067, at 310-301-3335, to discuss your rights free of charge. You can also reach us through the firm’s website at www.schallfirm.com, or by email at [email protected]

The Schall Law Firm represents investors around the world and specializes in securities class action lawsuits and shareholder rights litigation.

This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and rules of ethics.

CONTACT:

The Schall Law Firm
Brian Schall, Esq.
310-301-3335
in[email protected]
www.schallfirm.com

SOURCE: The Schall Law Firm

RLMD – ONGOING INVESTIGATION NOTICE: The Schall Law Firm Announces it is Investigating Claims Against Relmada Therapeutics, Inc. and Encourages Investors with Losses to Contact the Firm

LOS ANGELES, CA / ACCESSWIRE / May 28, 2023 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Relmada Therapeutics, Inc. (“Relmada” or “the Company”) (NASDAQ: RLMD) for violations of the securities laws.

https://www.accesswire.com/users/newswire/images/718659/1schall-logo.jpg

The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors. Relmada announced the results of its RELIANCE III study of drug REL-1017 on October 13, 2022. The Company disclosed that the trial did not reach its primary endpoint, and that “paradoxical results were observed in certain study sites, where [the] placebo dramatically outperformed REL-1017.” Based on this news, shares of Relmada dropped by almost 80% on the next day.

If you are a shareholder who suffered a loss, click here to participate.

We also encourage you to contact Brian Schall of the Schall Law Firm, 2049 Century Park East, Suite 2460, Los Angeles, CA 90067, at 310-301-3335, to discuss your rights free of charge. You can also reach us through the firm’s website at www.schallfirm.com, or by email at [email protected]

The class in this case has not yet been certified, and until certification occurs, you are not represented by an attorney. If you choose to take no action, you can remain an absent class member.

The Schall Law Firm represents investors around the world and specializes in securities class action lawsuits and shareholder rights litigation.

This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and rules of ethics.

CONTACT:

The Schall Law Firm
Brian Schall, Esq.
310-301-3335
[email protected]
www.schallfirm.com

SOURCE: The Schall Law Firm

IBRX – IMPORTANT INVESTOR NOTICE: The Schall Law Firm Announces it is Investigating Claims Against ImmunityBio, Inc. and Encourages Investors with Losses to Contact the Firm

LOS ANGELES, CA / ACCESSWIRE / May 28, 2023 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of ImmunityBio, Inc. (“ImmunityBio” or “the Company”) (NASDAQ: IBRX) for violations of the securities laws.

https://www.accesswire.com/users/newswire/images/718659/1schall-logo.jpg

The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors. ImmunityBio announced on May 11, 2023, that it “has received a complete response letter from the U.S. Food and Drug Administration (“FDA”) on May 9, 2023 regarding its Biologics License Application (“BLA”) for its product candidate, Anktiva™ (N-803) in combination with Bacillus Calmette-Guérin (“BCG”) for the treatment of patients with BCG-unresponsive non-muscle invasive bladder cancer (“NMIBC”) with carcinoma in situ (“CIS”) with or without Ta or T1 disease. The letter indicates that the FDA has determined that it cannot approve the BLA in its present form, and the FDA has made recommendations to address the issues raised.” Based on this news, shares of ImmunityBio fell by more than 54% in morning trading on the same day.

If you are a shareholder who suffered a loss, click here to participate.

We also encourage you to contact Brian Schall of the Schall Law Firm, 2049 Century Park East, Suite 2460, Los Angeles, CA 90067, at 310-301-3335, to discuss your rights free of charge. You can also reach us through the firm’s website at www.schallfirm.com, or by email at [email protected]

The class in this case has not yet been certified, and until certification occurs, you are not represented by an attorney. If you choose to take no action, you can remain an absent class member.

The Schall Law Firm represents investors around the world and specializes in securities class action lawsuits and shareholder rights litigation.

This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and rules of ethics.

CONTACT:

The Schall Law Firm
Brian Schall, Esq.
310-301-3335
[email protected]
www.schallfirm.com

SOURCE: The Schall Law Firm